These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 26188211

  • 1. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.
    Jhund PS, McMurray JJ, Chaturvedi N, Brunel P, Desai AS, Finn PV, Haffner SM, Solomon SD, Weinrauch LA, Claggett BL, Pfeffer MA.
    Eur Heart J; 2015 Sep 21; 36(36):2463-9. PubMed ID: 26188211
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register.
    Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbjörnsdottir S, Swedish National Diabetes Register.
    Diab Vasc Dis Res; 2013 Nov 21; 10(6):520-9. PubMed ID: 24002670
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
    So WY, Ozaki R, Chan NN, Tong PC, Ho CS, Lam CW, Ko GT, Chow CC, Chan WB, Ma RC, Chan JC.
    Hypertension; 2004 Sep 21; 44(3):294-9. PubMed ID: 15249544
    [Abstract] [Full Text] [Related]

  • 6. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators.
    N Engl J Med; 2009 Nov 19; 361(21):2019-32. PubMed ID: 19880844
    [Abstract] [Full Text] [Related]

  • 7. Urine IgM-excretion as a prognostic marker for progression of type 2 diabetic nephropathy.
    Tofik R, Torffvit O, Rippe B, Bakoush O.
    Diabetes Res Clin Pract; 2012 Jan 19; 95(1):139-44. PubMed ID: 22078636
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP, EXAMINE Investigators.
    Diabetes Care; 2016 Jul 19; 39(7):1267-73. PubMed ID: 27289121
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease.
    Sud M, Tangri N, Pintilie M, Levey AS, Naimark D.
    Circulation; 2014 Aug 05; 130(6):458-65. PubMed ID: 24899688
    [Abstract] [Full Text] [Related]

  • 11. Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction.
    Moejko-Pastewka B, Tatoń J, Haczyński J, Strojek K, Ametov AS, Milicevic Z.
    Acta Diabetol; 2003 Dec 05; 40 Suppl 2():S354-7. PubMed ID: 14704868
    [Abstract] [Full Text] [Related]

  • 12. Concomitant macro and microvascular complications in diabetic nephropathy.
    Alwakeel JS, Al-Suwaida A, Isnani AC, Al-Harbi A, Alam A.
    Saudi J Kidney Dis Transpl; 2009 May 05; 20(3):402-9. PubMed ID: 19414942
    [Abstract] [Full Text] [Related]

  • 13. Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes.
    Theilade S, Hansen TW, Rossing P.
    Am J Hypertens; 2014 Sep 05; 27(9):1152-9. PubMed ID: 24627444
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: A nationwide French observational study of hospitalized patients.
    Ducluzeau PH, Fauchier G, Herbert J, Semaan C, Halimi JM, Angoulvant D, Fauchier L.
    Diabetes Metab; 2023 May 05; 49(3):101429. PubMed ID: 36736892
    [Abstract] [Full Text] [Related]

  • 15. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
    Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW.
    Postgrad Med; 2010 May 05; 122(3):16-27. PubMed ID: 20463410
    [Abstract] [Full Text] [Related]

  • 16. Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes.
    Theilade S, Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P.
    Diabet Med; 2012 Aug 05; 29(8):990-4. PubMed ID: 22414297
    [Abstract] [Full Text] [Related]

  • 17. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr 05; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
    Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS, Zile MR, Anand IS, Wikstrand J, Wedel H, Komajda M, Carson PE, Cleland JG, McMurray JJ.
    Eur J Heart Fail; 2015 Feb 05; 17(2):169-76. PubMed ID: 25756844
    [Abstract] [Full Text] [Related]

  • 20. Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes.
    Afkarian M, Zelnick LR, Ruzinski J, Kestenbaum B, Himmelfarb J, de Boer IH, Mehrotra R.
    J Diabetes Complications; 2015 Feb 05; 29(8):1024-31. PubMed ID: 26412030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.